A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs PF 6649751 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 27 Oct 2017 Planned End Date changed from 27 Jun 2018 to 3 Feb 2018.
- 27 Oct 2017 Planned primary completion date changed from 30 May 2018 to 6 Jan 2018.
- 27 Oct 2017 Status changed from recruiting to active, no longer recruiting.